The new fund will mostly support biotechs making new drugs, with investments spanning from initial financings to follow-on ...
Detailed price information for Esperion Theraptc (ESPR-Q) from The Globe and Mail including charting and trades.
Uniting The Global Biopharma Community In Suzhou. Suzhou, China – March 12–14, 2026, The global biopharmaceutical industry ...
Daiichi Sankyo’s DS3610 enters clinical development in patients with advanced solid tumours: Tokyo Wednesday, November 12, 2025, 11:00 Hrs [IST] Daiichi Sankyo, an innovative gl ...
HER2 positive breast cancer treatment market was valued at USD 8.56 billion in 2024 and is projected to reach USD 18.67 billion by 2033, growing at a CAGR of 9.1% over the forecast period. China state ...
"By combining precise tumour targeting with an immunotherapy payload, Daiichi Sankyo is exploring a new way to harness the ...
Astute Analytica stands out as a premier provider of comprehensive Glass Frit and Paste Market research reports specifically tailored for the healthcare sector. Our commitment lies in delivering ...
The first patient has been dosed in a first-in-human phase 1 trial evaluating DS3610 in patients with advanced, metastatic or ...
Esperion Therapeutics stock remains a buy as strong drug franchises, growth, and global milestones outweigh risks. Learn more ...
Q3 2025 Earnings Call Transcript November 6, 2025 Esperion Therapeutics, Inc. misses on earnings expectations. Reported EPS ...
Zacks Investment Research on MSN
AZN Q3 Earnings Top Estimates, Sales Rise As Most Key Drugs Outperform
AstraZeneca’s AZN third-quarter 2025 core earnings of $1.19 per American depositary share (ADS) beat the Zacks Consensus Estimate of $1.14 per share. Core earnings of $2.38 per share rose 14% year ...
The “most favored nation” (MFN) drug pricing deal AstraZeneca recently signed with the Trump administration won’t affect the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback